Ohtuvayre Verona Pharma Ireland Limited · Application withdrawn · ATC R03BX
Therapeutic indication (EMA)
Maintenance treatment in symptomatic adult patients with chronic obstructive pulmonary disease (COPD).
Active substance
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| OHTUVAYRE | 3MG/2.5ML | suspension · inhalation | MSD | Prescription | 26 Jun 2024 |
Maintenance treatment in symptomatic adult patients with chronic obstructive pulmonary disease (COPD).
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.